INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas

Trial ID or NCT#

NCT04295759

Status

not recruiting iconNOT RECRUITING

Purpose

This is a multicenter phase 1 trial of INCB7839 for children with recurrent or progressive high-grade gliomas, including, but not limited to, diffuse intrinsic pontine glioma (DIPG) and other diffuse midline gliomas (DMGs), after upfront therapy.

Official Title

A Phase I Study of the Adam-10 Inhibitor, INCB7839 in Children With Recurrent/Progressive High-Grade Gliomas to Target Microenvironmental Neuroligin-3

Eligibility Criteria

Ages Eligible for Study: 3 Years to 21 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No

Investigator(s)

Michelle Monje

Contact us to find out if this trial is right for you.

Contact

Erica Velasco
650-721-4083